Sentence examples for binding assays demonstrate that from inspiring English sources

In vivo DNA binding assays demonstrate that VNG0258H binds DNA to mediate gene regulation.

In vivo binding assays demonstrate that VNG0258H binds directly to the promoter of sod2, encoding the [Mn] superoxide dismutase.

The results of these RNA binding assays demonstrate that the Cdc5 N-terminus binds to RNA directly and that, of the three essential domains, Cdc5-D3 binds RNA more robustly than the canonical Myb repeats alone.

A ChIPseq analysis performed by Farnham and co-workers [19] and a locus-specific ChIP performed in this study show the binding of KAP1 to the TNDM1 ICR and in vitro binding assays demonstrate that this sequence is indeed able to bind hZFP57 if methylated.

In this report, surface plasmon resonance (SPR) experiments and solid-phase binding assays demonstrate that recombinant Cyr61 interacts with immobilized monomeric or multimeric vitronectin (VTNC) with KD in the nanomolar range.

Indeed, competitive binding assays demonstrated that ponatinib could directly bind RIPK1 i n vitro with high affinity (Kd: 37 nM).

The binding assays demonstrated that rMsEno was able to bind to chicken Plg and human Fn proteins.

In vitro cell binding assays demonstrated that the A33scFv-Fc produced by P. pastoris can bind GPA33-positive but not GPA-negative tumor cells.

Quantitative in vitro binding assays demonstrated that RBR-2 is required for high affinity binding of EIAV Rev; ERRE fragments containing both RBR-1 and RBR-2 have much higher affinity for EIAV Rev than those lacking RBR-2 (Figure S1).

Moreover, in vitro peptide binding assays demonstrated that the affinity of 14 3 3 for S28 phosphorylated peptides and H3S10K14 phosphoacetylated peptides is very similar [23].

Studies using knock-in mice and in vitro binding assays demonstrated that the T192M mutation affects the LG-binding modification of α-dystroglycan by disrupting its interaction with LARGE (i.e., formation of the enzyme substrate complex).